Aligos Therapeutics, Inc. Share Price & Technical Analysis
ALGS · $5.76 (+0.88%)
Healthcare / Biotechnology
$5.76
+0.88%
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosco…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-3% return in May, -12% avg return in past 3 year May month.
-43% return in 2026, 39% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -13% | -12% | 7% | -21% | -3% | – | – | – | – | – | – | – | -43% |
| 25 | -36% | -28% | -52% | -32% | -9% | 36% | 3% | 47% | -4% | -18% | 16% | -1% | -78% |
| 24 | 4% | 44% | -2% | -23% | -21% | -42% | 48% | -2% | -31% | 14% | 160% | 51% | 199% |
| 23 | 98% | -25% | -39% | 29% | -7% | -16% | -9% | -4% | -15% | -20% | 9% | -5% | -3% |
| 22 | -73% | -25% | -11% | -45% | 9% | -6% | 3% | 1% | -13% | -9% | -7% | -2% | -179% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$38.12M
P/E ratio
—
52W high
$13.69
52W low
$5.12
Volume
1,36,141
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aligos Therapeutics, Inc. share price today?
- Aligos Therapeutics, Inc. (ALGS) last traded around $5.76 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALGS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALGS. Download the app for real-time alerts.
- How can I analyze Aligos Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.